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Years of efforts have been invested in developing targeted
cancer therapies by identifying the unique features of can-
cer cells and designing specific molecules to eliminate
them while sparing their healthy neighbors. Spurred on
by the initial success of imatinib mesylate in treating Phil-
adelphia chromosome-positive leukemia, the emergence
of resistance to targeted therapies caught many off guard.
Where is the resistance coming from? What makes the
persisters special? And how might we stage a counterof-
fensive?Unexpected signaling crosstalk underlies resistance to targeted
therapy (Created by Caitlyn Webster; courtesy of Monique Dail and
Kevin Shannon).
The tyrosinekinase inhibitor ponatinib (orange) binds to theABL1T315I
kinase domain (upper) but not ABLE255V/T315I (lower, point mutants in
yellow) (Courtesy of Matthew Zabriskie and Nadeem Vellore).Leukemia has been a particular focal point for answering
these questions. Multiple tyrosine kinase inhibitors (TKIs)
have been developed to specifically target the leukemogenic
BCR-ABL1 fusion protein, and patients receiving such treat-
ments are known to develop not only single but also com-
pound mutants in the BCR-ABL1 gene that could confer
resistance. A study from the laboratories of Michael Dein-
inger and Thomas O’Hare (Zabriskie et al., 2014) takes a
close look at these compound mutations residing in the
kinase domain and establishes the sensitivity of different
compound mutants to various clinically available TKIs.
More importantly, they identify a group of compound mu-
tants classified by the inclusion of one killer mutant, T315I,as themost resistant to all TKIs, and their structural modeling
points could inform the design of a therapy targeting these
lethal combinations.
In addition to selecting point mutants in the target domain,
resistance can also be acquired in a more global and revers-
ible manner. Indeed, the work published earlier this year by
Bradley Bernstein and Michelle Kelliher (Knoechel et al.,
2014) looks into the resistance to g-secretase inhibitors
(GSIs) that target oncogenic NOTCH1 activation in T cell
acute lymphoblastic leukemia (T-ALL). What they have found
is that chromatin in persister cells exhibits different epige-
netic features that lead to distinct signaling programs and
even changes in nuclear sizes. They take advantage of the
reversible nature of epigenetic changes and show that by
combining GSI with a chromatin modifier inhibitor, the per-
sisters collapse.
A number of studies have reported that therapeutic resis-
tance can arise from aberrant activation of additional path-
ways that circumvent the effect of targeting the primary
oncogenic mechanism. An example of this is provided by
Michael Green’s group, who establish that inhibiting the
mitogen-activated protein kinase kinase (MEK) can effec-
tively eliminate stem cells in chronic myeloid leukemia trig-
gered by the BCR-ABL1 fusion protein (Ma et al., 2014).
While combinatory therapy that simultaneously targets two
oncogenic pathways has been proposed for combating
resistance in various contexts, recent work from Kevin
Shannon’s laboratory (Dail et al., 2014) suggest that this
strategy should be implemented cautiously because it could
inadvertently promote the selection of resistant cells. In
particular, they show that although upregulation of NOTCH1
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leukemic cells resistant to the combo treatment of PI3K and
MEK inhibitors exhibit reduced expression of NOTCH1 and
develop cross-resistance to inhibitors targeting NOTCH1
signaling. This work presents a previously unappreciated
scenario that instead of activating additional oncogenic
pathways, cancer cells resistant to targeted therapy may
actually dampen a major oncogenic signaling pathway,
which evidently serves as an indirect approach for cancer
cells to acquire resistance to the potential inhibition of a
key oncogenic signature, in this case NOTCH1 activation.
This unusual observation suggests that lack of NOTCH1
activation might be tumorigenic by releasing a brake on
PI3K signaling.
When it comes to resistance to cancer therapy, there is lit-
tle doubt that we are in for a protracted battle. Yet, we
shouldn’t forget how far we’ve come—from fantasizing
that targeted therapy is the ‘‘magic bullet’’ to seeing it as
an important avenue that is leading to a clearer view of
the complexity and evolvability of cancer. That we are faced
with resistance only means that we are getting closer to our
goal.
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